Clinical Study

Doxapram Use for Apnoea of Prematurity in Neonatal Intensive Care

Table 3

Short-term outcome of the patients who received doxapram.

TotalSuccessfully treated patients ( )Unsuccessfully treated patients ( )
(%) Median (IQR) (min–max)%Median (IQR)%Median (IQR)

Neonatal survival#117/122 (95.9)1/79 (98.7)4/37 (89.2)0.035
Number of ventilatory days7 (12) (0–72)5 (12)11 (13)<0.001
Number of NICU days38 (31) (6–120)33 (26)42 (34)0.002
Pneumothorax6/122 (4.9)3/76 (3.9)2/37 (5.4)0.65
Corticosteroids for detubation27/122 (22.1)11/79 (13.9)13/37 (35.1)0.013
NEC27/122 (22.1)15/79 (19.0)10/37 (27.0)0.34
IVH (all grades)40/122 (32.8)23/79 (29.1)16/37 (43.2)0.15
PVL (all grades)35/120 (29.2)19/78 (24.4)14/36 (38.9)0.13
Persistent ductus arteriosus44/122 (36.1)26/79 (32.9)14/37 (37.8)0.68
ROP17/112 (15.2)8/72 (11.1)7/34 (20.6)0.24

Mann-Whitney test and Fisher’s Exact test.
#No patients died during doxapram treatment.